drugset
drugset / Trial / NCT07115745

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745 ↗

Phase 1 Recruiting 125 enrolled Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory autoimmune diseases.

Timeline

Start
2025-09-04
Primary completion
2029-03-15
Completion
2030-08-16

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986515 Cell therapy — —
Background Cyclophosphamide Other / unclassified — —
Background Fludarabine Small molecule — —
Background Tocilizumab Monoclonal antibody — —

Indications

No indication recorded.